Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro.

Fang Z, Wang J, Clark LH, Sun W, Yin Y, Kong W, Pierce SR, West L, Sullivan SA, Tran AQ, Prabhu VV, Zhou C, Bae-Jump V.

Am J Cancer Res. 2018 Aug 1;8(8):1551-1563. eCollection 2018.

2.

Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells.

Xu G, Fang Z, Clark LH, Sun W, Yin Y, Zhang R, Sullivan SA, Tran AQ, Kong W, Wang J, Zhou C, Bae-Jump VL.

Am J Transl Res. 2018 Jun 15;10(6):1663-1676. eCollection 2018.

3.

Targeted Multiplex Gene Expression Profiling to Measure High-Fat Diet and Metformin Effects on Fetal Gene Expression in a Mouse Model.

Vora NL, Grace MR, Smeester L, Dotters-Katz SK, Fry RC, Bae-Jump V, Boggess K.

Reprod Sci. 2018 Jan 1:1933719118786453. doi: 10.1177/1933719118786453. [Epub ahead of print]

PMID:
29976116
4.

Erratum: Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.

Jones HM, Fang Z, Sun W, Clark LH, Stine JE, Tran AQ, Sullivan SA, Gilliam TP, Zhou C, Bae-Jump VL.

Am J Cancer Res. 2018 May 1;8(5):915. eCollection 2018.

5.

Novasoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways.

Malloy KM, Wang J, Clark LH, Fang Z, Sun W, Yin Y, Kong W, Zhou C, Bae-Jump VL.

Am J Transl Res. 2018 Mar 15;10(3):784-795. eCollection 2018.

6.

Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese versus lean mice.

Han J, Wysham WZ, Zhong Y, Guo H, Zhang L, Malloy KM, Dickens HK, Huh G, Lee D, Makowski L, Zhou C, Bae-Jump VL.

Oncotarget. 2017 Sep 8;8(67):110965-110982. doi: 10.18632/oncotarget.20754. eCollection 2017 Dec 19.

7.

Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.

Jones HM, Fang Z, Sun W, Clark LH, Stine JE, Tran AQ, Sullivan SA, Gilliam TP, Zhou C, Bae-Jump VL.

Am J Cancer Res. 2017 Dec 1;7(12):2478-2490. eCollection 2017. Erratum in: Am J Cancer Res. 2018 May 01;8(5):915.

8.

Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer.

Jackson AL, Sun W, Kilgore J, Guo H, Fang Z, Yin Y, Jones HM, Gilliam TP, Zhou C, Bae-Jump VL.

Oncotarget. 2017 Oct 24;8(59):100113-100127. doi: 10.18632/oncotarget.22012. eCollection 2017 Nov 21.

9.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC.

Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13. Review.

10.

Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer.

Sun L, Yin Y, Clark LH, Sun W, Sullivan SA, Tran AQ, Han J, Zhang L, Guo H, Madugu E, Pan T, Jackson AL, Kilgore J, Jones HM, Gilliam TP, Zhou C, Bae-Jump VL.

Oncotarget. 2017 Jun 29;8(38):63551-63561. doi: 10.18632/oncotarget.18854. eCollection 2017 Sep 8.

11.

VprBP/DCAF1 Regulates the Degradation and Nonproteolytic Activation of the Cell Cycle Transcription Factor FoxM1.

Wang X, Arceci A, Bird K, Mills CA, Choudhury R, Kernan JL, Zhou C, Bae-Jump V, Bowers A, Emanuele MJ.

Mol Cell Biol. 2017 Jun 15;37(13). pii: e00609-16. doi: 10.1128/MCB.00609-16. Print 2017 Jul 1.

12.

Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule.

Witek MA, Aufforth RD, Wang H, Kamande JW, Jackson JM, Pullagurla SR, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, Perou CM, Soper JT, Whang YE, Yeh JJ, Martin G, Soper SA.

NPJ Precis Oncol. 2017;1. pii: 24. doi: 10.1038/s41698-017-0028-8. Epub 2017 Jul 25.

13.

Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer.

Yuan L, Sheng X, Clark LH, Zhang L, Guo H, Jones HM, Willson AK, Gehrig PA, Zhou C, Bae-Jump VL.

Am J Transl Res. 2016 Oct 15;8(10):4265-4277. eCollection 2016.

14.

Deregulated miRNAs in human cervical cancer: functional importance and potential clinical use.

Li J, Liu Q, Clark LH, Qiu H, Bae-Jump VL, Zhou C.

Future Oncol. 2017 Apr;13(8):743-753. doi: 10.2217/fon-2016-0328. Epub 2016 Nov 3. Review.

PMID:
27806630
15.

The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.

Suri A, Sheng X, Schuler KM, Zhong Y, Han X, Jones HM, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Jun 28;7(26):39582-39594. doi: 10.18632/oncotarget.8659.

16.

NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo.

Zhang L, Han J, Jackson AL, Clark LN, Kilgore J, Guo H, Livingston N, Batchelor K, Yin Y, Gilliam TP, Gehrig PA, Sheng X, Zhou C, Bae-Jump VL.

J Hematol Oncol. 2016 Sep 21;9(1):91.

17.

JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.

Qiu H, Li J, Clark LH, Jackson AL, Zhang L, Guo H, Kilgore JE, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Oct 11;7(41):66809-66821. doi: 10.18632/oncotarget.11631.

18.

Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.

Kilgore J, Jackson AL, Clark LH, Guo H, Zhang L, Jones HM, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL.

Am J Transl Res. 2016 Jun 15;8(6):2705-15. eCollection 2016.

19.

Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project.

Roque DR, Makowski L, Chen TH, Rashid N, Hayes DN, Bae-Jump V.

Gynecol Oncol. 2016 Aug;142(2):317-22. doi: 10.1016/j.ygyno.2016.06.006. Epub 2016 Jun 14.

20.

SIX1 Oncoprotein as a Biomarker in a Model of Hormonal Carcinogenesis and in Human Endometrial Cancer.

Suen AA, Jefferson WN, Wood CE, Padilla-Banks E, Bae-Jump VL, Williams CJ.

Mol Cancer Res. 2016 Sep;14(9):849-58. doi: 10.1158/1541-7786.MCR-16-0084. Epub 2016 Jun 3.

21.

Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines.

Wysham WZ, Roque DR, Han J, Zhang L, Guo H, Gehrig PA, Zhou C, Bae-Jump VL.

Target Oncol. 2016 Dec;11(6):763-769.

PMID:
27188391
22.

Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.

Guo H, Zhong Y, Jackson AL, Clark LH, Kilgore J, Zhang L, Han J, Sheng X, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Apr 12;7(15):20338-56. doi: 10.18632/oncotarget.7934.

23.

Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.

Giovinazzo H, Kumar P, Sheikh A, Brooks KM, Ivanovic M, Walsh M, Caron WP, Kowalsky RJ, Song G, Whitlow A, Clarke-Pearson DL, Brewster WR, Van Le L, Zamboni BA, Bae-Jump V, Gehrig PA, Zamboni WC.

Cancer Chemother Pharmacol. 2016 Mar;77(3):565-73. doi: 10.1007/s00280-015-2945-y. Epub 2016 Jan 28.

PMID:
26822231
24.

Adjuvant Treatment and Clinical Trials in Elderly Patients With Endometrial Cancer: A Time for Change?

Clark LH, Jackson AL, Gehrig PA, Bae-Jump V, Van Le L, Ko EM.

Int J Gynecol Cancer. 2016 Feb;26(2):282-9. doi: 10.1097/IGC.0000000000000605.

PMID:
26745698
25.

Knockdown of hTERT and Treatment with BIBR1532 Inhibit Cell Proliferation and Invasion in Endometrial Cancer Cells.

Kong W, Lv N, Wysham WZ, Roque DR, Zhang T, Jiao S, Song D, Chen J, Bae-Jump VL, Zhou C.

J Cancer. 2015 Nov 1;6(12):1337-45. doi: 10.7150/jca.13054. eCollection 2015.

26.

Endometrial Cancer Survivors' Perceptions of Provider Obesity Counseling and Attempted Behavior Change: Are We Seizing the Moment?

Clark LH, Ko EM, Kernodle A, Harris A, Moore DT, Gehrig PA, Bae-Jump V.

Int J Gynecol Cancer. 2016 Feb;26(2):318-24. doi: 10.1097/IGC.0000000000000596.

PMID:
26588234
27.

Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian Cancer.

Barber EL, Boggess JF, Van Le L, Kim KH, Bae-Jump VL, Brewster WR, Soper JT, Gehrig PA.

Obstet Gynecol. 2015 Dec;126(6):1191-7. doi: 10.1097/AOG.0000000000001138.

PMID:
26551182
28.

Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis.

Secord AA, Hasselblad V, Von Gruenigen VE, Gehrig PA, Modesitt SC, Bae-Jump V, Havrilesky LJ.

Gynecol Oncol. 2016 Jan;140(1):184-90. doi: 10.1016/j.ygyno.2015.10.020. Epub 2015 Oct 31. Review.

PMID:
26524722
29.

The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.

Stine JE, Guo H, Sheng X, Han X, Schointuch MN, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Jan 5;7(1):946-60. doi: 10.18632/oncotarget.5834.

30.

Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling.

Han J, Zhang L, Guo H, Wysham WZ, Roque DR, Willson AK, Sheng X, Zhou C, Bae-Jump VL.

Gynecol Oncol. 2015 Sep;138(3):668-75. doi: 10.1016/j.ygyno.2015.06.036. Epub 2015 Jun 30.

31.

Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.

Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoshchenko RG, Hanna SK, Ramanathan RK, Lee CR, Bae-Jump VL, Gehrig PA, Zamboni WC.

Nanomedicine. 2015 Oct;11(7):1797-807. doi: 10.1016/j.nano.2015.05.007. Epub 2015 Jun 17.

PMID:
26093057
32.

Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway.

Yuan L, Sheng X, Willson AK, Roque DR, Stine JE, Guo H, Jones HM, Zhou C, Bae-Jump VL.

Endocr Relat Cancer. 2015 Aug;22(4):577-91. doi: 10.1530/ERC-15-0192. Epub 2015 Jun 4.

33.

Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.

Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Ramón y Cajal T, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van Maerken T, Díez O, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, de la Hoya M, Caldés T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR; Teixeira, Hogervorst FB, van der Hout AH, Seynaeve C, van der Luijt RB, Ligtenberg MJ, Devilee P, Wijnen JT, Rookus MA, Meijers-Heijboer HE, Blok MJ, van den Ouweland AM, Aalfs CM, Rodriguez GC, Phillips KA, Piedmonte M, Nerenstone SR, Bae-Jump VL, O'Malley DM, Ratner ES, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Bojesen A, Pedersen IS, Sunde L, Jensen UB, Thomassen M, Kruse TA, Foretova L, Peterlongo P, Bernard L, Peissel B, Scuvera G, Manoukian S, Radice P, Ottini L, Montagna M, Agata S, Maugard C, Simard J, Soucy P, Berger A, Fink-Retter A, Singer CF, Rappaport C, Geschwantler-Kaulich D, Tea MK, Pfeiler G; BCFR, John EM, Miron A, Neuhausen SL, Terry MB, Chung WK, Daly MB, Goldgar DE, Janavicius R, Dorfling CM, van Rensburg EJ, Fostira F, Konstantopoulou I, Garber J, Godwin AK, Olah E, Narod SA, Rennert G, Paluch SS, Laitman Y, Friedman E; SWE-BRCA, Liljegren A, Rantala J, Stenmark-Askmalm M, Loman N, Imyanitov EN, Hamann U; kConFab Investigators, Spurdle AB, Healey S, Weitzel JN, Herzog J, Margileth D, Gorrini C, Esteller M, Gómez A, Sayols S, Vidal E, Heyn H; GEMO, Stoppa-Lyonnet D, Léoné M, Barjhoux L, Fassy-Colcombet M, de Pauw A, Lasset C, Ferrer SF, Castera L, Berthet P, Cornelis F, Bignon YJ, Damiola F, Mazoyer S, Sinilnikova OM, Maxwell CA, Vijai J, Robson M, Kauff N, Corines MJ, Villano D, Cunningham J, Lee A, Lindor N, Lázaro C, Easton DF, Offit K, Chenevix-Trench G, Couch FJ, Antoniou AC, Pujana MA.

PLoS One. 2015 Apr 1;10(4):e0120020. doi: 10.1371/journal.pone.0120020. eCollection 2015.

34.

Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer.

Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, Borowsky ME, Gibb RK.

Cancer. 2015 Jul 1;121(13):2108-20. doi: 10.1002/cncr.29321. Epub 2015 Mar 27. Review.

35.

JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.

Qiu H, Jackson AL, Kilgore JE, Zhong Y, Chan LL, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2015 Mar 30;6(9):6915-30.

36.

Comprehensive care in gynecologic oncology: The importance of palliative care.

Landrum LM, Blank S, Chen LM, Duska L, Bae-Jump V, Lee PS, Levine L, McCourt C, Moore KN, Urban RR.

Gynecol Oncol. 2015 May;137(2):193-202. doi: 10.1016/j.ygyno.2015.02.026. Epub 2015 Mar 4. No abstract available.

PMID:
25749723
37.

Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells.

Han X, Sheng X, Jones HM, Jackson AL, Kilgore J, Stine JE, Schointuch MN, Zhou C, Bae-Jump VL.

J Hematol Oncol. 2015 Jan 29;8:2. doi: 10.1186/s13045-014-0097-x.

38.

Enzymatic cleavage of uracil-containing single-stranded DNA linkers for the efficient release of affinity-selected circulating tumor cells.

Nair SV, Witek MA, Jackson JM, Lindell MA, Hunsucker SA, Sapp T, Perry CE, Hupert ML, Bae-Jump V, Gehrig PA, Wysham WZ, Armistead PM, Voorhees P, Soper SA.

Chem Commun (Camb). 2015 Feb 21;51(15):3266-9. doi: 10.1039/c4cc09765c.

39.

Metformin and the risk of endometrial cancer: a population-based cohort study.

Ko EM, Stürmer T, Hong JL, Castillo WC, Bae-Jump V, Funk MJ.

Gynecol Oncol. 2015 Feb;136(2):341-7. doi: 10.1016/j.ygyno.2014.12.001. Epub 2014 Dec 8.

PMID:
25499603
40.

Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.

Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, Bae-Jump VL.

Cancer Med. 2015 Feb;4(2):161-73. doi: 10.1002/cam4.353. Epub 2014 Nov 21.

41.

Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity to improve patient-centered outcomes.

Doll KM, Kalinowski AK, Snavely AC, Irwin DE, Bensen JT, Bae-Jump VL, Kim KH, Van Le L, Clarke-Pearson DL, Gehrig PA.

Cancer. 2015 Feb 1;121(3):395-402. doi: 10.1002/cncr.29061. Epub 2014 Sep 23.

42.

Metformin and gynecologic cancers.

Stine JE, Bae-Jump V.

Obstet Gynecol Surv. 2014 Aug;69(8):477-89. doi: 10.1097/OGX.0000000000000092. Review.

PMID:
25144611
43.

Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.

Wang J, Ma X, Jones HM, Chan LL, Song F, Zhang W, Bae-Jump VL, Zhou C.

J Transl Med. 2014 Aug 21;12:226. doi: 10.1186/s12967-014-0226-x.

44.

Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.

Schointuch MN, Gilliam TP, Stine JE, Han X, Zhou C, Gehrig PA, Kim K, Bae-Jump VL.

Gynecol Oncol. 2014 Aug;134(2):346-55. doi: 10.1016/j.ygyno.2014.05.015. Epub 2014 May 28.

45.

Preoperative quality of life and surgical outcomes in gynecologic oncology patients: a new predictor of operative risk?

Doll KM, Snavely AC, Kalinowski A, Irwin DE, Bensen JT, Bae-Jump V, Boggess JF, Soper JT, Brewster WR, Gehrig PA.

Gynecol Oncol. 2014 Jun;133(3):546-51. doi: 10.1016/j.ygyno.2014.04.002. Epub 2014 Apr 12.

46.

Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer.

Makowski L, Zhou C, Zhong Y, Kuan PF, Fan C, Sampey BP, Difurio M, Bae-Jump VL.

Gynecol Oncol. 2014 Apr;133(1):90-7. doi: 10.1016/j.ygyno.2013.12.026.

47.

The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance.

Ko EM, Walter P, Clark L, Jackson A, Franasiak J, Bolac C, Havrilesky L, Secord AA, Moore DT, Gehrig PA, Bae-Jump VL.

Gynecol Oncol. 2014 Apr;133(1):28-32. doi: 10.1016/j.ygyno.2014.01.032.

PMID:
24680588
48.

Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer.

Previs RA, Kilgore J, Craven R, Broadwater G, Bean S, Wobker S, DiFurio M, Bae-Jump V, Gehrig PA, Secord AA.

Int J Gynecol Cancer. 2014 May;24(4):670-5. doi: 10.1097/IGC.0000000000000109.

49.

Metformin is associated with improved survival in endometrial cancer.

Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA, Bae-Jump V.

Gynecol Oncol. 2014 Feb;132(2):438-42. doi: 10.1016/j.ygyno.2013.11.021. Epub 2013 Nov 22.

PMID:
24269517
50.

Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology.

Caron WP, Lay JC, Fong AM, La-Beck NM, Kumar P, Newman SE, Zhou H, Monaco JH, Clarke-Pearson DL, Brewster WR, Van Le L, Bae-Jump VL, Gehrig PA, Zamboni WC.

J Pharmacol Exp Ther. 2013 Dec;347(3):599-606. doi: 10.1124/jpet.113.208801. Epub 2013 Sep 16.

Supplemental Content

Loading ...
Support Center